Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

US Real-world Migraine-related Health Care Resource Utilization and Costs for Patients Initiating Fremanezumab
Headache
Headache Posters (7:00 AM-5:00 PM)
051

Fremanezumab is a fully-humanized monoclonal antibody (IgG2Δa) that selectively targets the calcitonin gene-related peptide (CGRP) and is approved for the preventive treatment of migraine in adults. Decision makers need data on real-world impact of fremanezumab treatment on resource utilization to inform choice of preventive treatment.

This US real-world, retrospective claims analysis evaluated health care resource utilization in patients with chronic or episodic migraine (CM/EM) initiating fremanezumab treatment.

The IBM/MarketScan Research Commercial and Medicare supplemental database, which contains health care service and outpatient prescription data for US insurance beneficiaries, was used to identify adult patients (age ≥18 years) with ≥1 pharmacy claim for fremanezumab between October 1, 2018 through December 31, 2018 (date of earliest claim was index date); ≥1 CM or EM diagnosis; and 6 months of medical and pharmacy utilization data pre-index (baseline) and post-index (follow-up).

691 eligible migraine patients were identified. The mean±SD age at index was 45.0±11.8 years, and the majority of patients were female (86%). Most patients (79%) had EM. During the the 6 months pre-index versus the 6 months post-index, statistically significantly higher mean±SD numbers of migraine-related inpatient visits (0.03±0.19 vs 0.01±0.11), migraine-related emergency room (ER) visits (0.12±0.57 vs 0.09±0.44), migraine-related outpatient visits (2.17±2.79 vs 1.87±2.77), and migraine-related acute medication prescription claims (4.96±5.10 vs 4.12±4.96; all P<0.05) were reported. Mean±SD migraine-related outpatient costs ($419.30±723.29 vs $302.13±505.41) and migraine-related acute medication costs ($706.76±1,812.39 vs $519.65±1,506.41) were statistically significantly higher in the 6 months pre-index versus the 6 months post-index (both P <0.001). Migraine-related inpatient and migraine-related ER costs did not differ statistically significantly during the 6 months pre- and post-index.

Fremanezumab treatment is associated with statistically significant reductions in migraine-related inpatient, ER, and outpatient visits; acute medication prescriptions; and outpatient and acute medication costs in the first 6 months of use.

Authors/Disclosures
Michael Seminerio
PRESENTER
Michael Seminerio has received personal compensation for serving as an employee of AbbVie.
Krishna Tangirala (Teva ;Pharmaceuticals) Krishna Tangirala has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Stephen F. Thompson Stephen Thompson has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Rinat Ariely Rinat Ariely has received personal compensation for serving as an employee of Teva Pharmaceuticals. Rinat Ariely has received stock or an ownership interest from Teva Pharmaceuticals.
Joshua *use 125685 Cohen (Teva Pharmaceuticals Industries) Joshua Cohen has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Karen Carr (Teva) Karen Carr has received stock or an ownership interest from Teva Pharmaceuticals. An immediate family member of Karen Carr has received stock or an ownership interest from Genentech.
Dawn C. Buse, PhD (Dawn C. Buse, PhD) Dr. Buse has received personal compensation for serving as an employee of Vector Psychometric Group. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Collegium. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Buse has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Pain and Headache Reports. The institution of Dr. Buse has received research support from Amgen. The institution of Dr. Buse has received research support from FDA. The institution of Dr. Buse has received research support from National Headache Foundation.